4-{1-(carboxymethyl)-5-fluoro-7-[(E)-2-(4-{[(2E)-4-phenoxy-2-buten-1-yl]oxy}phenyl)vinyl]-1H-indol-3-yl}butanoic acid | 908136-20-9

• 分子结构分类: 有机化合物
• 英文名称: 4-{1-(carboxymethyl)-5-fluoro-7-[(E)-2-(4-{[(2E)-4-phenoxy-2-buten-1-yl]oxy}phenyl)vinyl]-1H-indol-3-yl}butanoic acid
• 英文别名: 4-[1-(carboxymethyl)-5-fluoro-7-[(E)-2-[4-[(E)-4-phenoxybut-2-enoxy]phenyl]ethenyl]indol-3-yl]butanoic acid
• CAS: 908136-20-9
• 化学式: C₃₂H₃₀FNO₆
• 分子量: 543.592
• InChiKey: FOMPBAWQPRQSLN-CTLAPNPFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  40
• 可旋转键数：
  14
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  98
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Indole Compound and Use Thereof
  申请人：Takeuchi Jun

  公开号：US20080188532A1

  公开（公告）日：2008-08-07

  The present invention relates to a compound represented by the formula (I), wherein all symbols are as defined in the description, a salt thereof, a solvate thereof, or a prodrug thereof, which has a leukotriene receptor antagonistic activity which is expected to be more effective than those of the leukotriene receptor antagonists currently used in clinical trials. Therefore, it is useful as an agent for the prevention and/or treatment of a leukotriene-mediated disease such as a respiratory diseases such as bronchial asthma, chronic obstructive pulmonary disease, pulmonary emphysema, chronic bronchitis, pneumonia (e.g. interstitial pneumonia etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), allergic rhinitis, sinusitis (e.g. acute sinusitis, chronic sinusitis, etc.), or the like, or as an expectorant or an antiitussive.

  本发明涉及一种化合物，其表示为公式（I），其中所有符号如描述中所定义，其盐，溶剂化物或前药，具有期望比目前在临床试验中使用的白三烯受体拮抗剂更有效的白三烯受体拮抗作用。因此，它可用作预防和/或治疗白三烯介导的疾病，例如呼吸系统疾病，如支气管哮喘，慢性阻塞性肺疾病，肺气肿，慢性支气管炎，肺炎（例如间质性肺炎等），严重急性呼吸综合征（SARS），急性呼吸窘迫综合征（ARDS），过敏性鼻炎，鼻窦炎（例如急性鼻窦炎，慢性鼻窦炎等），或作为祛痰剂或止咳剂。
• INDOLE COMPOUND AND USE THEREOF
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1852420A1

  公开（公告）日：2007-11-07

  The present invention relates to a compound represented by the formula (I), wherein all symbols are as defined in the description, a salt thereof a solvate thereof, or a prodrug thereof, which has a leukotriene receptor antagonistic activity which is expected to be more effective than those of the leukotriene receptor antagonists currently used in clinical trials. Therefore, it is useful as an agent for the prevention and/or treatment of a leukotriene-mediated disease such as a respiratory diseases such as bronchial asthma, chronic obstructive pulmonary disease, pulmonary emphysema, chronic bronchitis, pneumonia (e.g. interstitial pneumonia etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), allergic rhinitis, sinusitis (e.g. acute sinusitis, chronic sinusitis, etc.), or the like, or as an expectorant or an antitussive.

  本发明涉及一种由式 (I) 代表的化合物、 本发明涉及一种由式（I）表示的化合物，其中所有符号如描述中所定义，它的盐，它的溶解物，或它的原药，它具有白三烯受体拮抗活性，预计比目前用于临床试验的白三烯受体拮抗剂更有效。因此，它可用作预防和/或治疗白三烯介导的疾病的药物，如支气管哮喘、慢性阻塞性肺病、肺气肿、慢性支气管炎、肺炎（如间质性肺炎等）等呼吸系统疾病。如间质性肺炎等）、严重急性呼吸系统综合征（SARS）、急性呼吸窘迫综合征（ARDS）、过敏性鼻炎、鼻窦炎（如急性鼻窦炎、慢性鼻窦炎等）等，或作为祛痰剂或抗鼻炎药。
• Indole compounds for treating respiratory disorders
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1852420B1

  公开（公告）日：2012-10-17
• US7728023B2
  申请人：——

  公开号：US7728023B2

  公开（公告）日：2010-06-01